52 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
LLY Eli Lilly and Company $105.71 $113.53B N/A
Article Searches
Company News for Jan 13, 2020 http://www.zacks.com/stock/news/715585/company-news-for-jan-13-2020?cid=CS-ZC--corporate_summary-715585 Jan 13, 2020 - Companies In The News Are: SNX, KBH, WDFC, LLY.
J&J Seeks Label Expansion for Spravato Nasal Spray in EU http://www.zacks.com/stock/news/720650/jj-seeks-label-expansion-for-spravato-nasal-spray-in-eu?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-720650 Jan 16, 2020 - J&J (JNJ) seeks label expansion for its new nasal spray, Spravato (esketamine), for an expanded patient population in Europe.
Eli Lilly's Shopping Spree Won't Stop With Dermira, CFO Shares Plans For More Deals In 2020 https://www.fool.com/investing/2020/01/17/eli-lillys-shopping-spree-wont-stop-with-dermira-c.aspx?source=iedfolrf0000001 Jan 17, 2020 - The Midwest's largest drugmaker isn't finished making mid-sized deals.
Top Stock Analyst Reports for Pfizer, Wells Fargo & SAP http://www.zacks.com/research-daily/729250/top-stock-analyst-reports-for-pfizer-wells-fargo-sap?cid=CS-ZC-FT-research_daily-729250 Jan 22, 2020 - Top Stock Analyst Reports for Pfizer, Wells Fargo & SAP
Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year? http://www.zacks.com/stock/news/734952/has-eli-lilly-and-lly-outpaced-other-medical-stocks-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-734952 Jan 27, 2020 - Is (LLY) Outperforming Other Medical Stocks This Year?
Eli Lilly (LLY) Tops Q4 Earnings & Sales, Keeps 2020 View http://www.zacks.com/stock/news/740479/eli-lilly-lly-tops-q4-earnings-sales-keeps-2020-view?cid=CS-ZC-FT-tale_of_the_tape|earnings_report-740479 Jan 30, 2020 - Eli Lilly's (LLY) Q4 earnings and sales beat estimates. Shares rise in pre-market trading.
Eli Lilly and Company (LLY) CEO Dave Ricks on Q4 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4320345-eli-lilly-and-company-lly-ceo-dave-ricks-on-q4-2019-results-earnings-call-transcript?source=feed_sector_healthcare Jan 30, 2020 - Eli Lilly and Company (NYSE:LLY) Q4 2019 Earnings Conference Call January 30, 2020 09:00 a.m. ET Company Representatives Dave Ricks - Chairman, Chief Executive Officer Josh Smiley - Chief Financial Of
Lilly's NDA for Selpercatinib Gets FDA's Priority Review http://www.zacks.com/stock/news/740824/lillys-nda-for-selpercatinib-gets-fdas-priority-review?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-740824 Jan 30, 2020 - Lilly's (LLY) NDA for oral RET inhibitor selpercatinib gains the FDA priority review status for RET-altered lung and thyroid cancers.
Teva's Two Pivotal Studies on Ajovy in Japan Meet Goal http://www.zacks.com/stock/news/748888/tevas-two-pivotal-studies-on-ajovy-in-japan-meet-goal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-748888 Feb 04, 2020 - Teva (TEVA) posts positive results from two phase II/III studies on Ajovy for treating patients with chronic and episodic migraine in Japan.
Eli Lilly and Incyte Record Another Positive Clinical Trial for Olumiant Works in Eczema https://www.fool.com/investing/2020/02/12/eli-lilly-and-incyte-record-another-positive-clini.aspx?source=iedfolrf0000001 Feb 12, 2020 - The drug moves closer to an expanded approval for the skin disorder.

Pages: 123456

<<<Page 5